Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties

Ambros V . (2004). The functions of animal microRNAs. Nature 431: 350–355.

Braconi C, Patel T . (2008). MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology 47: 1807–1809.

Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. (2008). Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897–907.

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004.

Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM . (2008). Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 82: 8215–8223.

Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA et al. (2004). miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1: 106–113.

Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW et al. (2008). Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48: 1810–1820.

Coulouarn C, Factor VM, Thorgeirsson SS . (2008). Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059–2067.

Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA et al. (2006). Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 44: 1003–1011.

Czech MP . (2006). MicroRNAs as therapeutic targets. N Engl J Med 354: 1194–1195.

El-Serag HB . (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27–S34.

Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452: 896–899.

Esau C, Davis S, Murray SF, Yu XX, Pandey SK et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87–98.

Esquela-Kerscher A, Slack FJ . (2006). Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.

Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A . (2008). miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48: 648–656.

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG et al. (2007). Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092–6099.

Grise F, Bidaud A, Moreau V . (2009). Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795: 137–151.

Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C et al. (2008). microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 27: 3300–3310.

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P . (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577–1581.

Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS . (2006). Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582–1595.

Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS et al. (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28: 6773–6784.

Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al. (2006). Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99: 671–678.

Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S et al. (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955–1963.

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735–739.

Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al. (2004a). Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.

Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK et al. (2004b). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306–1311.

Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al. (2006). A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410–416.

Lee JS, Thorgeirsson SS . (2002). Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 35: 1134–1143.

Li W, Xie L, He X, Li J, Tu K, Wei L et al. (2008). Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123: 1616–1622.

Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL . (2008). miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 375: 315–320.

Lu J, Getz G, Miska EA, varez-Saavedra E, Lamb J, Peck D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834–838.

Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T et al. (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537–2545.

Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL et al. (2004). Control of pancreas and liver gene expression by HNF transcription factors. Science 303: 1378–1381.

Parkin DM, Bray F, Ferlay J, Pisani P . (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.

Tang X, Gal J, Zhuang X, Wang W, Zhu H, Tang G . (2007). A simple array platform for microRNA analysis and its application in mouse tissues. RNA 13: 1803–1822.

Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147–152.

Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM et al. (2009). MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571–1582.

Thorgeirsson SS, Grisham JW . (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339–346.

Thorgeirsson SS, Lee JS, Grisham JW . (2006). Functional genomics of hepatocellular carcinoma. Hepatology 43: S145–S150.

Tzur G, Levy A, Meiri E, Barad O, Spector Y, Bentwich Z et al. (2008). MicroRNA expression patterns and function in endodermal differentiation of human embryonic stem cells. PLoS ONE 3: e3726.

Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP et al. (2008). MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223–1232.

Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM . (2007). Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55–76.

Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF et al. (2008). MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257–269.

Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C et al. (2008). DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22: 1439–1444.

Yoshioka K, Imamura F, Shinkai K, Miyoshi J, Ogawa H, Mukai M et al. (1995). Participation of rhop21 in serum-dependent invasion by rat ascites hepatoma cells. FEBS Lett 372: 25–28.